Abstract Details

Title VLA-4 Antisense [ndash] An Oligonucleotide Targeting VLA-4 mRNA (ATL1102) Significantly Reduces New Active Lesions in Patients with RR-MS

Topic MS and Related Diseases

Presentation(s) (-)

Poster/Presentation
Number 001

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Volker Limmroth, MD, PhD (City of Cologne / Cologne General Hospital (Merheim))	No disclosure on file
Frederik Barkhof, MD, PhD (Image Analysis Center)	Frederik Barkhof has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Frederik Barkhof has received personal compensation in the range of $0-$499 for serving as a Consultant for Biogen. Frederik Barkhof has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Combinostics. Frederik Barkhof has received personal compensation in the range of $500-$4,999 for serving as a Consultant for IXICO. Frederik Barkhof has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Frederik Barkhof has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EISAI.
	No disclosure on file
Sumit Verma, MD (Emory Children's Center)	Dr. Verma has nothing to disclose.

��ɫ��